CaPtivate is a development stage pharmaceutical company focused on
developing novel vaccines for injection or mucosal administration through its
patented proprietary calcium phosphate (CaP) nanoparticle technology platform.
In addition to applications in non-invasive drug
delivery, protein purification, as a dietary supplement, and in esthetic
medicine, our CaP nanoparticle
technology has originally been developed as a safe and effective vaccine
adjuvant for injection or mucosal administration. Extensive preclinical data have been generated which
show CaP’s ability to increase vaccines’
immunogenicity after injection or needle-free routes. CaP
technology has successfully completed a single dose pre-clinical toxicity study
for the administration of CaP orally, into muscles,
under the skin, and into the lungs. Also, in a Phase I “safety and toxicity”
study conducted under an approved IND in the U.S., CaP has been shown safe to administer in healthy human
subjects by injection. CaP nanoparticle technology
demonstrated promise to enhance immune response to vaccines, while improving
effectiveness and safety profiles, often leading to the use of lower vaccine
dosage. As a new company with an impressive portfolio of preclinical vaccine
data available for, CaPtivate identified the
following vaccines for further development using CaP nanoparticle adjuvant CaPtiVantTM:
- Seasonal or pandemic Influenza vaccines for injection and/or mucosal administration.
- A new hepatitis B vaccine for mucosal administration.
- Herpes simplex-2 vaccine for mucosal administration
While
continue developing its vaccine program to address significant public health
needs, CaPtivate is also making its CaP technology available through exclusive
or non-exclusive licensing.
